Risk of Major Bleeding Not Reduced by Lower-dose Heparin Use During Coronary Procedure

by Kathy Jones on  September 02, 2010 at 7:59 PM Heart Disease News
  •   Print
  •   Share
  •   Comments
  •  Text 
A study that will appear in the September 22 issue of JAMA says that patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure and received a lower dose of the anticoagulant heparin during the procedure did not have a reduced rate of major bleeding and vascular access site complications.

The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

Previous study results suggested the use of unfractionated heparin as supplemental therapy at the time of percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) for patients with non-ST segment elevation (a certain pattern on an electrocardiogram) acute coronary syndromes (such as heart attack or unstable angina) who were treated with fondaparinux and undergoing PCI. But there is disagreement on the appropriate range of dosing of heparin during PCI for these patients, according to background information in the article. "The optimal dosing of unfractionated heparin should maintain the safety profile of fondaparinux but achieve adequate antithrombin effect to prevent catheter thrombus [blood clots]," the authors write.

Sanjit S. Jolly, M.D., of Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada, and colleagues with the Fondaparinux Trial With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes (FUTURA)/OASIS-8 trial evaluated the safety of two dose regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients. The randomized trial included 179 hospitals in 18 countries and involved 2,026 patients undergoing PCI within 72 hours, who were from a group of 3,235 high-risk patients with non-ST segment elevation acute coronary syndromes initially treated with fondaparinux, enrolled from February 2009 to March 2010. Patients received intravenously either low-dose unfractionated heparin (50 U/kg, regardless of use of glycoprotein IIb-IIIa [GpIIb-IIIa] inhibitors) or standard-dose unfractionated heparin (85 U/kg [60 U/kg with GpIIb-IIIa inhibitors]), adjusted by activated clotting time (ACT).

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X
  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
News Categories:  
Kidney Health Center

Heart Disease Related News

» Health of Folks With Heart Failure Better With Nordic Walking » Sudden Cardiac Death Linked to Slower Electrical Currents: Study
» Intake of Calcium Supplements Double Heart Attack Risk » Thousands Of Lives Can be Saved From Heart Attacks By Simple Checks
» Retinal Vessel Diameter and CVD Risk in African Americans With Type 1 Diabetes: Study » Research Sheds Light on Open Heart Surgery and Kidney Disease Patients
» History of Palpitation Increases Risk of Atrial Fibrillation » Aortic Aneurysm Treatment can be Monitored by Contrast-Enhanced Ultrasound
Read More >>